Melanocortin-4 receptor (MC4R) agonists for the treatment of obesity

Journal of Medicinal Chemistry

Volumn 49, Issue 14, 2006, Pages 4035-4043

  Nargund, Ravi P ^a   Strack, Alison M ^a   Fong, Tung M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; DEXFENFLURAMINE; HISTIDYL DEXTRO TRYPTOPHYLALANYLTRYPTOPHYL DEXTRO PHENYLALANYLLYSINAMIDE; IMIDAZOPYRIDINE DERIVATIVE; MELANOCORTIN; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN 4 RECEPTOR AGONIST; MELANOCORTIN AGONIST; MK 0678; N TERT BUTYLPYRROLIDINE DERIVATIVE; NEUROPEPTIDE Y; PEPTIDE AGONIST; PEPTIDE ANTAGONIST; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

DRUG MECHANISM; HUMAN; NAUSEA; NEUROPHYSIOLOGY; NONHUMAN; OBESITY; SEXUAL FUNCTION; SHORT SURVEY; STRUCTURE ACTIVITY RELATION; VOMITING; WEIGHT REDUCTION;

ALPHA-MSH; ANIMALS; ANTI-OBESITY AGENTS; BRAIN; DRUG DESIGN; HUMANS; LIGANDS; MODELS, MOLECULAR; OBESITY; OLIGOPEPTIDES; RECEPTOR, MELANOCORTIN, TYPE 4; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; STRUCTURE-ACTIVITY RELATIONSHIP; SYNAPTIC TRANSMISSION;

EID: 33745827397     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm058241a     Document Type: Short Survey

References (100)

1. Kishi, T.; Aschkenasi, C. J.; Lee, C. E.; Mountjoy, K. G.; Saper, C. B.; et al. Expression of melanocortin 4 receptor mRNA in the central nervous system of the rat. J. Comp. Neurol. 2003, 457, 213-235.
2. Cone, R. D.; Lu, D.; Koppula, S.; Vage, D. I.; Klugland, H.; et al. The melanocortin receptors: agonists, antagonists, and the hormonal control of pigmentation. Recent Prog. Horm. Res. 1996, 51, 287-318.
3. Hadley, M. E.; Hruby, V. J.; Jiang, J.; Sharma, S. D.; Fink, J. L.; et al. Melanocortin receptors: identification and characterization by melanotropic peptide agonists and antagonists. Pigm. Cell Res. 1996, 9, 213-234.
4. 2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. J. Med. Chem. 1995, 38, 3454-3461.
5. Rosen, R. C.; Diamond, L. E.; Earle, D. C.; Shadiack, A. M.; Molinoff, P. B. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int. J. Impotence Res. 2004, 16, 135-142.
6. Pfaus, J.; Shadiack, A.; Soest, T. V.; Tse, M.; Molinoff, P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 10201-10204.
7. Chu, X. J.; Bartkovitz, D.; Danho, W.; Swistok, J.; Cheung, A. W.; et al. Bioorg. Med. Chem. Lett. 2005, 15, 4910-4914.
8. MacNeil, D. J.; Howard, A. D.; Guan, X.; Fong, T. M.; Nargund, R. P.; et al. The role of melanocortins in body weight regulation: opportunities for the treatment of obesity. Eur. J. Pharmacol. 2002, 450, 93-109.
9. Irani, B.; Holder, J.; Todorovic, A.; Wilczynski, A.; Joseph, C.; et al. Progress in the development of melanocortin receptor selective ligands. Curr. Pharm. Des. 2004, 10, 3443-3479.
10. Huszar, D.; Lynch, C. A.; Fair-Huntress, V.; Dunmore, J. H.; Fang, Q.; et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997, 88, 131-141.
11. Farooqi, I. S.; Keogh, J. M.; Yeo, G. S.; Lank, E. J.; Cheetham, T.; et al. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N. Engl. J. Med. 2003, 348, 1085-1095.
12. Yeo, G. S.; Lank, E. J.; Farooqi, I. S.; Keogh, J.; Challis, B. G.; et al. Mutations in the human melanocortin-4 receptor gene associated with severe familial obesity disrupt receptor function through multiple molecular mechanisms. Hum. Mol. Genet. 2003, 12, 561-574.
13. Biebermann, H.; Krude, H.; Elsner, A.; Chubanov, V.; Gudermann, T.; et al. Autosomal-dominant mode of inheritance of a melanocortin-4 receptor mutation in a patient with severe early-onset obesity is due to a dominant-negative effect caused by receptor dimerization. Diabetes 2003, 52, 2984-2988.
14. Hirschhorn, J. N.; Altshuler, D. Once and again-issues surrounding replication in genetic association studies. J. Clin. Endocrinol. Metab. 2002, 87, 4438-4441.
15. Nijenhuis, W. A.; Garner, K. M.; van Rozen, R. J.; Adan, R. A. Poor cell surface expression of human melanocortin-4 receptor mutations associated with obesity. J. Biol. Chem. 2003, 278, 22939-22945.
16. Lubrano-Berthelier, C.; Durand, E.; Dubern, B.; Shapiro, A.; Dazin, P.; et al. Intracellular retention is a common characteristic of childhood obesity-associated MC4R mutations. Hum. Mol. Genet. 2003, 12, 145-153.
17. Farooqi, I. S.; Yeo, G. S.; Keogh, J. M.; Aminian, S.; Jebb, S. A.; et al. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J. Clin. Invest. 2000, 106, 271-279.
18. Schioth, H. B.; Raudsepp, T.; Ringholm, A.; Fredriksson, R.; Takeuchi, S.; et al. Remarkable synteny conservation of melanocortin receptors in chicken, human, and other vertebrates. Genomics 2003, 81, 504-509.
19. Ringholm, A.; Fredriksson, R.; Poliakova, N.; Yan, Y. L.; Postlethwait, J. H.; et al. One melanocortin 4 and two melanocortin 5 receptors from zebrafish show remarkable conservation in structure and pharmacology. J. Neurochem. 2002, 82, 6-18.
20. Song, Y.; Golling, G.; Thacker, T. L.; Cone, R. D. Agouti-related protein (AGRP) is conserved and regulated by metabolic state in the zebrafish, Danio rerio. Endocrine 2003, 22, 257-265.
21. Murphy, B.; Nunes, C; Ronan, J.; Harper, C; Beall, M.; et al. Melanocortin mediated inhibition of feeding behavior in rats. Neuropeptides 1998, 32 (6), 491-497.
22. Fan, W.; Boston, B. A.; Kesterson, R. A.; Hruby, V. J.; Cone, R. D. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 1997, 385, 65-68.
23. Hwa, J. J.; Ghibaudi, L.; Gao, J.; Parker, E. M. Central melanocortin system modulates energy intake and expenditure of obese and lean Zucker rats. Am. J. Physiol.: Regul., Integr. Comp. Physiol. 2001, 281 (2), R444-R451.
24. Grill, H. J.; Ginsberg, A. B.; Seeley, R. J.; Kaplan, J. M. Brainstem application of melanocortin receptor ligands produces long-lasting effects on feeding and body weight. J. Neurosci. 1998, 18, 10128-10135.
25. Rossi, M.; Kim, M. S.; Morgan, D. G. A.; Small, C. J.; Edwards, C. M. B.; et al. A C-terminal fragment of agouti-related protein increases feeding and antagonizes the effect of alpha-melanocyte stimulating hormone in vivo. Endocrinology 1998, 139 (10), 4428-4431.
26. Chen, A. S.; Metzger, J. M.; Trumbauer, M. E.; Guan, X.-M.; Yu, H.; et al. Role of the melanocortin-4 receptor in metabolic rate and food intake in mice. Transgenic Res. 9 (2), 2000, 9 (2), 145-154.
27. Goto, K.; Inui, A.; Takimoto, Y.; Yuzuriha, H.; Asakawa, A.; et al. Acute intracerebroventricular administration of either carboxyl-terminal or amino-terminal fragments of agouti-related peptide produces a long-term decrease in energy expenditure in rats. Int. J. Mol. Med. 2003, 12 (3), 379-383.
28. Kim, M.; Rossi, M.; Abusnana, S.; Sunter, D.; Morgan, D.; et al. Hypothalamic localization of the feeding effect of agouti-related peptide and alpha-melanocyte-stimulating hormone. Diabetes 2000, 49, 177-182.
29. Cabeza de Vaca, S.; Kim, G.; Carr, K. The melanocortin receptor agonist MTII augments the rewarding effect of amphetamine in adlibitum-fed and food-restricted rats. Psychopharmacology (Berlin) 2002, 161 (1), 77-85.
30. Kishi, T.; Aschkenasi, C. J.; Lee, C. E.; Mountjoy, K. G.; Saper, C. B.; et al. Expression of melanocortin 4 receptor mRNA in the central nervous system of the rat. J. Comp. Neurol. 2003, 457, 213-235.
31. Kelley, A. E.; Berridge, K. C. The Neuroscience of Natural Rewards: Relevance to Addictive Drugs. J. Neurosci. 2002, 22, 3306-3311.
32. Azzara, A. V.; Sokolnicki, J. P.; Schwartz, G. J. Central melanocortin receptor agonist reduces spontaneous and scheduled meal size but does not augment duodenal preload-induced feeding inhibition. Physiol. Behav. 2002, 77 (2), 411-416.
33. Williams, D.; Grill, H.; Weiss, S.; Baird, J.; Kaplan, J. Behavioral processes underlying the intake suppressive effects of melanocortin 3/4 receptor activation in the rat. Psychopharmacology (Berlin) 2002, 161 (1), 47-53.
34. Bluher, S.; Ziotopoulou, M.; Bullen, J. W., Jr.; Moschos, S. J.; Ungsunan, L.; et al. Responsiveness to Peripherally administered melanocortins in lean and obese mice. Diabetes 2004, 53, 82-90.
35. Hansen, M. J.; Ball, M. J.; Morris, M. J. Enhanced inhibitory feeding response to alpha-melanocyte stimulating hormone in the diet-induced obese rat. Brain Res. 2001, 892, 130-137.
36. Kim, Y.-W.; Choi, D.-W.; Park, Y.-H.; Huh, J.-Y.; Won, K.-C.; et al. Leptin-like effects of MTII are augmented in MSG-obese rats. Regul. Pept. 2005, 127, 63-70.
37. Li, G.; Zhang, Y.; Wilseyand, J.; Scarpace, P. Unabated anorexic and enhanced thermogenic responses to MTII in diet-induced obese rats despite reduced melanocortin 3/4 receptor expression. J. Endocrinol. 2004, 182, 123-132.
38. Clegg, D. J.; Benoit, S. C.; Air, E. L.; Jackman, A.; Tso, P.; et al. Increased dietary fat attenuates the anorexic effects of intracerebroventricular injections of MTII. Endocrinology 2003, 144, 2941-2946.
39. Fan, W.; Dinulescu, D. M.; Butler, A. A.; Zhou, J.; Marks, D. L.; et al. The central melanocortin system can directly regulate serum insulin levels. Endocrinology 2000, 141, 3072-3079.
40. Obici, S.; Feng, Z.; Tan, J.; Liu, L.; Karkanias, G.; et al. Central melanocortin receptors regulate insulin action. J. Clin. Invest. 2001, 108, 1079-1085.
41. Ste. Marie, L.; Miura, G. I.; Marsh, D. J.; Yagaloff, K.; Palmiter, R. D. A metabolic defect promotes obesity in mice lacking melanocortin-4 receptors. Proc. Natl. Acad. Sci. U S A 2000, 47, 12339-12344.
42. Fan, W.; Boston, B. A.; Kesterson, R. A.; Hruby, V. J.; Cone, R. D. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 1997, 385, 165-168.
43. Bednarek, M. A.; Fong, T. M. Ligands of the melanocortin receptors, 2002-2003 update. Expert Opin. Ther. Pat. 2004, 14, 327-336.
44. Boyce, R. S.; Duhl, D. M. Melanocortin-4 receptor agonists for the treatment of obesity. Curr. Opin. Invest. Drugs 2004, 5, 1063-1071.
45. Patchett, A. A.; Nargund, R. Privileged structures. An update. In Annual Reports in Medicinal Chemistry; Doherty, A, M., Ed.; Academic Press: San Diego, CA, 2000; Vol. 35, pp 289-298.
46. Cappelli, A.; Giuliani, G.; Mohr, G. P.; Gallelli, A.; Anzini, M. M.; et al. A non-peptide NK1 receptor agonist showing subpicomolar affinity. J. Med. Chem. 2004, 47, 1315-1318.
47. Sebhat, I. K.; Martin, W. J.; Ye, Z.; Barakat, K.; Mosley, R. T.; et al. Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium-3- ylcarbonyl]-(1R)-1-(4-chlorobenzyl)-2-[4-cyclohexyl-4-(1H-1,2, 4-triazol-1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist. J. Med. Chem. 2002, 45, 4589-4593.
48. Cepoi, D.; Phillips, T.; Cismowski, M.; Goodfellow, V. S.; Ling, N.; et al. Assessment of a small molecule melanocortin-4 receptor-specific agonist on energy homeostasis. Brain Res. 2004, 1000, 64-71.
49. Richardson, T. I.; Ornstein, P.; Briner, K.; Fisher, M. J.; Backer, R. T.; et al. Synthesis and structure-activity relationships of novel arylpiperazines as potent and selective agonists of the melanocortin subtype-4 receptor. J. Med. Chem. 2004, 47, 744-755.
50. Fotsch, C.; Han, N.; Arasasingham, P.; Bo, Y.; Carmouche, M.; et al. Bioorg. Med. Chem. Lett. 2005, 15 (6), 1623-1627.
51. Tran, J. A.; Pontillo, J.; Arellano, M.; White, N. S.; Fleck, B. A.; Marinkovic, D.; et al. Identification of agonists and antagonists of the human melanocortin-4 receptor from piperazinebenzylamines. Bioorg. Med. Chem. Lett. 2005, 15, 833-837.
52. Mutulis, F.; Yahorava, S.; Mutule, I.; Yahorau, A.; Leipinsh, E.; Kopantshuk, S.; et al. New substituted piperazines as ligands for melanocortin receptors. Correlation to the X-ray structure of "THIQ". J. Med. Chem. 2004, 47, 4613-4626.
53. Dyck, B.; Parker, J.; Phillips, T.; Carter, L.; Murphy, B.; Summers, R.; et al. Aryl piperazine MC4 receptor agonists. Bioorg. Med. Chem. Lett. 2003, 13, 3793-3796.
54. Palucki, B. L.; Park, M. K.; Nargund, R. P.; Ye, Z.; Sebhat, I. K.; et al. Discovery of (2S)-N-[(1R)-2-[4-Cyclohexyl-4-[[(1,1-dimethylethyl)amino] carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl] -4-methyl-2-piperazinecarboxamide (MB243), a potent and selective melanocortin subtype-4 receptor agonist. Bioorg. Med. Chem. Lett. 2005, 15, 171-175.
55. Doss, G. A.; Miller, R. R.; Zhang, Z.; Teffera, Y.; Nargund, R. P.; et al. Metabolic activation of a 1,3-disubstituted piperazine derivative: evidence for a novel ring contraction to an imidazoline. Chem. Res. Toxicol. 2005, 18, 271-276.
56. Ruel, R.; Herpin, T. F.; Iben, L.; Luo, G.; Martel, A.; et al. Beta-alanine dipeptides as MC4R agonists. Bioorg. Med. Chem. Lett. 2003, 13, 4341-4344.
57. Xi, N.; Hale, C.; Kelly, M. G.; Norman, M. H.; Stec, M.; et al. Synthesis of novel melanocortin 4 receptor agonists and antagonists containing a succinamide core. Bioorg. Med. Chem. Lett. 2004, 14, 377-381.
58. Ying, J.; Klover, K.; Gu, X.; Han, G.; Trivedi, D. B.; et al. Solution structures of cyclic melanocortin agonists and antagonists by NMR. Biopolymers 2003, 71, 696-716.
59. Ujjainwalla, F.; Warner, D.; Walsh, T. F.; Wyvratt, M. J.; Zhou, C.; et al. Design and Syntheses of melanocortin subtype-4 receptor agonists: evolution of the pyridazinone archetype. Bioorg. Med. Chem. Lett. 2003, 13, 4431-4435.
60. Pan, K.; Scott, M. K.; Lee, D. H. S.; Fitzpatrick, L. J.; Crooke, J. J.; et al. 2,3-Diaryl-5-anilino[1,2,4]thiadiazoles as melanocortin MC4 receptor agonists and their effects on feeding behavior in rats. Bioorg. Med. Chem. Lett. 2003, 11, 185-192.
61. Renhowe, R. A.; Chu, D.; Boyce, R.; Ni, Z.; Duhl, D.; et al. PCT Patent Application WO 0218327, 2002.
62. Boyce, R. S.; Aurrecoechea, N.; Chu, D.; Smith, A.; Conlee, C. R.; et al. Guanidino-substituted quinazolinone compounds as MC4-R agonists. PCT Patent Application WO 2004/112793, 2004.
63. Xiao, L. L.; Boyce, R. M.; Luo, L.; Johnson, K.; Frey, W. H., II; et al. Intranasal administration of MC4-R agonists. PCT Patent Application WO-03072056, 2003.
64. Ujjainwalla, F.; Chu, L.; Goulet, M. T.; Lee, B.; Warmer, D.; et al. PCT Patent Application WO 0268388, 2002.
65. Sings, H.; Ujjainwalla, F. Piperidine derivatives as melanocortin-4 receptor agonists. PCT Patent Application 2005/009950, 2005.
66. Poitout, L.; Brault, V.; Sackur, C.; Roubert, P.; Plas, P. Imidazopyridine derivatives as melanocortin receptor agonists. PCT Patent Application WO 2004/089951, 2004.
67. Sebhat, I.; Ye, Z.; Bednarek, M.; Weinberg, D.; Nargund, R.; et al. Melanocortin-4 receptor agonists and antagonists: chemistry and potential therapeutic utilities. In Annual Reports in Medicinal Chemistry; Doherty, A. M., Ed.; Academic Press: San Diego, CA, 2000; Vol. 38, pp 40-49.
68. Yang, Y. K.; Fong, T. M.; Dickinson, C. J.; Mao, C.; Li, J. Y.; et al. Molecular determinants of ligand binding to the human melanocortin-4 receptor. Biochemistry 2000, 39, 14900-14911.
69. Haskell-Luevano, C.; Cone, R. D.; Monck, E. K.; Wan, Y. P. Structure activity studies of the melanocortin-4 receptor by in vitro mutagenesis: identification of agouti-related protein (AGRP), melanocortin agonist, and synthetic peptide antagonist interaction determinants. Biochemistry 2001, 40, 6164-6179.
70. Nickolls, S. A.; Cismowski, M. I.; Wang, X.; Wolff, M.; Conlon, P. J.; et al. Molecular determinants of melanocortin 4 receptor ligand binding and MC4/MC3 receptor selectivity. J. Pharmacol. Exp. Ther. 2003, 304, 1217-1227.
71. Cox, A.; Donnelly, D.; Kaur, M.; Cheetham, S. C.; Cockcroft, V. B.; et al. MTSEA prevents ligand binding to the human melanocortin-4 receptor by modification of cysteine 130 in transmembrane helix 3. FEBS Lett. 2005, 579, 285-291.
72. Cowley, M. A.; Pronchuk, N.; Fan, W.; Dinulescu, D. M.; Colmers, W. F.; et al. Integration of NPY, AGRP and melanocortin signals in the hypothalamic paraventricular nucleus. Neuron 1999, 24, 155-163.
73. Fong, T. M.; Van der Ploeg, L. H. A melanocortin agonist reduces neuronal firing rate in rat hypothalamic slices. Neurosci. Lett. 2000, 283, 5-8.
74. Kishi, T.; Aschkenasi, C. J.; Choi, B. J.; Lopez, M. E.; Lee, C. E.; et al. Neuropeptide Y Y1 receptor mRNA in rodent brain: distribution and colocalization with melanocortin-4 receptor. J. Comp. Neurol. 2005, 482, 217-243.
75. Hagan, M. M.; Rushing, P. A.; Benoit, S. C.; Woods, S. C.; Seeley, R. J. Opioid receptor involvement in the effect of AgRP-(83-132) on food intake and food selection. Am. J. Physiol.: Regul., Integr. Comp. Physiol. 2001, 280 (3), R814-R821.
76. Olszewski, P. K.; Wirth, M. M.; Grace, M. K.; Levine, A. S.; Giraudo, S. Q. Evidence of interactions between melanocortin and opioid systems in regulation of feeding. NeuroReport 2001, 12, 1727-1730.
77. Alvaro, J. D.; Tatro, J. B.; Quillan, J. M.; Fogliano, M.; Eisenhard, M.; et al. Morphine down-regulates melanocortin-4 receptor expression in brain regions that mediate opiate addiction. Mol. Pharmacol. 1996, 50, 583-591.
78. Heisler, L. K.; Cowley, M. A.; Tecott, L. H.; Fan, W.; Low, M. J.; et al. Activation of central melanocortin pathways by fenfluramine. Science 2002, 297, 609-611.
79. Chen, H. Y.; Trumbauer, M. E.; Chen, A. S.; Weingarth, D. T.; Adams, J. R.; et al. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. Endocrinology 2004, 145, 2607-2612.
80. Cowley, M. A.; Smith, R. G.; Diano, S.; Tschop, M.; Pronchuk, N.; et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 2003, 37, 649-661.
81. Martin, W. J.; MacIntyre, D. Melanocortin receptors and erectile function. Eur. Urol. 2004, 45, 706-713.
82. Wessells, H.; Gralnek, D.; Dorr, R.; Hruby, V. J.; Hadley, M. E.; et al. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology 2000, 56, 641-646.
83. Martin, W. J.; McGowan, E.; Cashen, D. E.; Gantert, L. T.; Drisko, J. E.; et al. Activation of melanocortin MC(4) receptors increases erectile activity in rats ex copula. Eur. J. Pharmacol. 2002, 454, 71-79.
84. Van der Ploeg, L. H. T.; Martin, W. J.; Howard, A. D.; Nargund, R. P.; Austin, C. P.; et al. A role for the melanocortin 4 receptor in sexual function. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 11381-11386.
85. Wessells, H.; Hruby, V. J.; Hackett, J.; Han, G.; Balse-Srinivasan, P.; Vanderah, T. W. Ac-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-NH2 induces penile erection via brain and spinal melanocortin receptors. Neuroscience 2003, 118, 755-762.
86. Diamond, L. E.; Earle, D. C.; Rosen, R. C.; Willett, M. S.; Molinoff, P. B. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int. J. Impotence Res. 2004, 16, 51-59.
87. Fong, T. M.; Mao, C.; MacNeil, T.; Kalyani, R.; Smith, T.; et al. ART (protein product of agouti-related transcript) as an antagonist of MC3 and MC4 receptors. Biochem. Biophys. Res. Commun. 1997, 237, 629-631.
88. Ollmann, M. M.; Wilson, B. D.; Yang, Y.-K.; Kerns, J. A.; Chen, Y.; et al. Science 1997, 278, 135-138.
89. Shutter, J. R.; Gramham, M.; Kinsey, A. C.; Scully, S.; Luthy, R.; et al. Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice. Gene Dev. 1997, 11, 593-602.
90. Makimura, H.; Mizuno, T. M.; Mastaitis, J. W.; Agami, R.; Mobbs, C. V. Reducing hypothalamic AGRP by RNA interference increases metabolic rate and decreases body weight without influencing food intake. BMC Neurosci. 2002, 3, 18.
91. Nijenhuis, W. A.; Oosterom, J.; Adan, R. A. AgRP(83-132) acts as an inverse agonist on the human-melanocortin-4 receptor. Mol. Endocrinol. 2001, 15, 164-171.
92. Chai, B. X.; Neubig, R. R.; Millhauser, G. L.; Thompson, D. A.; Jackson, P. J.; et al. Inverse agonist activity of agouti and agouti-related protein. Peptides 2003, 24, 603-609.
93. Srinivasan, S.; Lubrano-Berthelier, C.; Govaerts, C.; Picard, F.; Santiago, P.; et al. Constitutive activity of the melanocortin-4 receptor is maintained by its N-terminal domain and plays a role in energy homeostasis in humans. J. Clin. Invest. 2004, 114, 1158-1162.
94. Korner, J.; Arronne, L. J. Pharmacological approaches to weight reduction: therapeutic targets. J. Clin. Endocrinol. Metab. 2004, 89, 2616-2621.
95. Verty, A. N. A.; McFarlane, J. R.; McGregor, I. S.; Mallet, P. E. Evidence for an interaction between CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake. Endocrinology 2004, 145, 3224-3231.
96. Vergoni, A.; Bertolini, A.; Wikberg, J.; Schioth, H. Corticotropin- releasing factor (CORTICOTROPIN RELEASING FACTOR) induced anorexia is not influenced by a melanocortin 4 receptor blockage. Peptides 1999, 20, 509-513.
97. Fan, W.; Ellacott, K. L. J.; Halatchev, I. G.; Takahashi, K.; Yu, P.; et al. Cholecystokinin-mediated suppression of feeding involves the brainstem melanocortin system. Nat. Neurosci. 2004, 7, 335-336.
98. Navarro, M.; Cubero, I.; Knapp, D. J.; Thiele, T. E. MTII-induced reduction of voluntary ethanol drinking is blocked by pretreatment with AgRP-(83-132). Neuropeptides 2003, 37, 344.
99. Ploj, K.; Roman, E.; Kask, A.; Hyytia, P.; Schioth, H. B.; et al. Effects of melanocortin receptor ligands on ethanol intake and opioid peptide levels in alcohol-preferring AA rats. Brain Res. Bull. 2002, 59, 97-104.
100. Navarro, M.; Cubero, I.; Chen, A. S.; Chen, H. Y.; Knapp, D. J.; et al. Effects of melanocortin receptor activation and blockade on ethanol intake: A possible role for the melanocortin-4 receptor. Alcohol.: Clin. Exp. Res. 2005, 29 (6), 949-957.